不同类型专利产出对医药企业绩效的时滞效应研究
|
摘要
本文以2012—2017年128家中国医药上市公司为研究对象,综合使用皮尔森检验分析和多元回归分析等方法研究,结果表明不同类型专利产出对医药企业绩效的时滞效应存在差异性,其中发明专利对医药企业战略绩效影响的时滞效应最强,达到4年;其次为实用新型专利,实用新型专利对医药企业财务绩效的滞后效应最强为3年,而发明专利和外观设计专利对财务绩效时滞效应不显著。相关结论对于我国医药企业优化内部专利组合,改进专利运营策略,提升企业绩效具有重要理论指导意义。
Using the methods of Pearson test analysis and multiple regression analysis,this paper proposes that there are differences in the time-delay effect of different types of patent output on the performance of pharmaceutical enterprises,taking the 128 listed Chinese pharmaceutical companies as the research object from 2012 to 2017.Among them,invention patents have the strongest time-delay effect on the strategic performance of pharmaceutical enterprises,reaching 4 years,followed by utility model patents and design patents.The lag effect of utility model patent on the financial performance of pharmaceutical enterprises is the strongest for 3 years,and the time lag effect of invention patent and design patent on financial performance is not significant.The relevant conclusions of this study are of great theoretical significance to optimize the internal patent portfolio,improve the strategy of patent operation and improve the performance of pharmaceutical enterprises in China.
Using the methods of Pearson test analysis and multiple regression analysis,this paper proposes that there are differences in the time-delay effect of different types of patent output on the performance of pharmaceutical enterprises,taking the 128 listed Chinese pharmaceutical companies as the research object from 2012 to 2017.Among them,invention patents have the strongest time-delay effect on the strategic performance of pharmaceutical enterprises,reaching 4 years,followed by utility model patents and design patents.The lag effect of utility model patent on the financial performance of pharmaceutical enterprises is the strongest for 3 years,and the time lag effect of invention patent and design patent on financial performance is not significant.The relevant conclusions of this study are of great theoretical significance to optimize the internal patent portfolio,improve the strategy of patent operation and improve the performance of pharmaceutical enterprises in China.
引文
[1]Patrick Thomas. A Relationship between Technology Indicators and Stock Market Performance[J].Scientometrics, 2001, 51(1):319-333.
[2]谌凯,应向伟,吴叶青,等.基于专利分析和文献计量的我国医药制造业发展态势研究[J].科技管理研究,2018, 38(2):103-111.
[3]庞弘燊,宋亦兵,覃筱楚,等.广东省生物医药知识产权密集型产业对比分析[J].科技管理研究,2018, 38(1):92-102.
[4]付韬,杨志慧,秦震.京津冀区域医药产业专利合作网络结构及其对医药企业专利产出的影响[J].科技管理研究,2017,37(22):177-183.
[5]潘玮,孙伟伟,张世玉,等.医药专利分析领域研究热点探测及对中药专利分析的启示[J].现代情报, 2017, 37(3):148-152
[6]周煊,程立茹,王皓.技术创新水平越高企业财务绩效越好吗?——基于16年中国制药上市公司专利申请数据的实证研究[J].金融研究, 2012(8):166-179.
[7]唐恒,金志成.我国医药制造上市公司专利水平与公司业绩协整分析[J].科技管理研究, 2012, 32(8):180-183,188.
[8]王天歌,王金苗,袁红梅.基于专利维度的我国生物医药核心技术的识别与分析[J].情报杂志, 2016, 35(4):112-117,69.
[9]高军,索玮岚.科研机构科技资源投入与产出的多阶段时滞效应研究[J].管理评论,2018,30(8):69-78.
[10]孙金花,杜姣.时滞效应视角下风险投资、R&D投入与知识产出的动态均衡关系——基于协整与VECM模型的实证分析[J].科技进步与对策, 2018, 35(15):9-15.
[11]索玮岚,高军,陈锐.科研机构科技资源使用效益评估研究——基于时滞效应和关联效应视角[J].科学学研究, 2015,33(2):234-241.
[12]夏太寿,王园磊.基于专利组合的我国生物医药产业技术竞争情报研究[J].图书情报研究, 2017, 10(1):78-85.
[2]谌凯,应向伟,吴叶青,等.基于专利分析和文献计量的我国医药制造业发展态势研究[J].科技管理研究,2018, 38(2):103-111.
[3]庞弘燊,宋亦兵,覃筱楚,等.广东省生物医药知识产权密集型产业对比分析[J].科技管理研究,2018, 38(1):92-102.
[4]付韬,杨志慧,秦震.京津冀区域医药产业专利合作网络结构及其对医药企业专利产出的影响[J].科技管理研究,2017,37(22):177-183.
[5]潘玮,孙伟伟,张世玉,等.医药专利分析领域研究热点探测及对中药专利分析的启示[J].现代情报, 2017, 37(3):148-152
[6]周煊,程立茹,王皓.技术创新水平越高企业财务绩效越好吗?——基于16年中国制药上市公司专利申请数据的实证研究[J].金融研究, 2012(8):166-179.
[7]唐恒,金志成.我国医药制造上市公司专利水平与公司业绩协整分析[J].科技管理研究, 2012, 32(8):180-183,188.
[8]王天歌,王金苗,袁红梅.基于专利维度的我国生物医药核心技术的识别与分析[J].情报杂志, 2016, 35(4):112-117,69.
[9]高军,索玮岚.科研机构科技资源投入与产出的多阶段时滞效应研究[J].管理评论,2018,30(8):69-78.
[10]孙金花,杜姣.时滞效应视角下风险投资、R&D投入与知识产出的动态均衡关系——基于协整与VECM模型的实证分析[J].科技进步与对策, 2018, 35(15):9-15.
[11]索玮岚,高军,陈锐.科研机构科技资源使用效益评估研究——基于时滞效应和关联效应视角[J].科学学研究, 2015,33(2):234-241.
[12]夏太寿,王园磊.基于专利组合的我国生物医药产业技术竞争情报研究[J].图书情报研究, 2017, 10(1):78-85.